Evidence map›Paper›PMID 35248100›Full record

ArticleRadiation oncology (London, England)2022

Postoperative lymphatic recurrence distribution and delineation of the radiation field in lower thoracic squamous cell esophageal carcinomas: a real-world study.

Rongxu Du, Songqing Fan, Xiaobin Wang, Xia Hou, Cheng Zeng, Dan Guo, Rongrong Tian, Dan Yang, Leilei Jiang, Xin Dong and 6 more

Open access · goldAbstract read
In one paragraph

Article in Radiation oncology (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Rongxu Du *Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, People's Republic of China.
Songqing Fan *Oncology Division I, China Pingmei Shenma Medical Group General Hospital, Kuanggongzhong Rd.1, Xinhua District, Pingdingshan, 450052, Henan, People's Republic of China.
Xiaobin WangDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University and Hebei Cancer Hospital, JianKang Rd.12, Shijiazhuang, 050011, Hebei, People's Republic of China.
Xia HouDepartment of Radiation Oncology, Shanxi Cancer Hospital, No.3 Workers New Village, Xinghualing District, Taiyuan, 030013, Shanxi, People's Republic of China.
Cheng ZengDepartment of Radiation Oncology, Central Theater General Hospital, Wuluo Rd.627, Wuchang District, Wuhan, 430061, Hubei, People's Republic of China.
Dan GuoDepartment of Radiation Oncology, Shanxi Cancer Hospital, No.3 Workers New Village, Xinghualing District, Taiyuan, 030013, Shanxi, People's Republic of China.
Rongrong TianDepartment of Radiation Oncology, Shanxi Cancer Hospital, No.3 Workers New Village, Xinghualing District, Taiyuan, 030013, Shanxi, People's Republic of China.
Dan YangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, People's Republic of China.
Leilei JiangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, People's Republic of China.
Xin DongKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, People's Republic of China.
Rong YuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, People's Republic of China.
Huiming YuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, People's Republic of China.
Dongming LiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, People's Republic of China.
Shuchai Zhu *Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University and Hebei Cancer Hospital, JianKang Rd.12, Shijiazhuang, 050011, Hebei, People's Republic of China. sczhu1965@163.com.
Jie Li *Department of Radiation Oncology, Shanxi Cancer Hospital, No.3 Workers New Village, Xinghualing District, Taiyuan, 030013, Shanxi, People's Republic of China. lijie942003@163.com.
Anhui Shi *Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, People's Republic of China. anhuidoctor@163.com.ORCID http://orcid.org/0000-0001-8463-1974
Peking University · CNShanxi Provincial Cancer Hospital · CNHebei Medical University · CNShenhua Group (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo study lymphatic recurrence distribution after radical surgery in the real world and guide clinical tumor volume delineation for regional lymph nodes during postoperative radiotherapy for lower thoracic squamous cell esophageal carcinomas.

methodsWe enrolled patients who underwent radical esophagectomy, without radiation before or after surgery, at 3 cancer hospitals. Patients were classified into groups according to tumor locations. We included patients with tumors in the lower thoracic segment and analyzed the postoperative lymph node recurrence mode. A cutoff value of 10% was used to differentiate high-risk lymph node drainage areas from others.

resultsWe enrolled 1905 patients in the whole study series, including 652 thoracic esophageal carcinomas that met our inclusion criteria; there were 241 cases of lower thoracic esophageal carcinomas. 1st, 2nd, 4th, 7th, 8th groups of lymph nodes, according to the 8th edition of the AJCC classification, displayed as high-risk recurrence areas, representing 17.8%, 23.9%, 11.7%, 10.9% and 12.2% of lymph node recurrence. Stage III-IV tumors located in the lower segment of the thoracic esophagus showed a tendency to recur in the left gastric nodes (7.9%) and celiac nodes (10.6%).

conclusionsAccording to our results, we recommended including the 4th, 7th and 8th groups of lymph nodes in the radiation field, and for patients with stage III-IV disease, the 17th and 20th groups of nodes should be irradiated during postoperative treatment. Whether including 1st/2nd groups in preventive irradiation needed more proofs.

Indexed as

EsophagectomyAdultAgedAged, 80 and overCombined Modality TherapyEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaFemaleHumansLymphatic MetastasisMaleMiddle AgedNeoplasm Recurrence, LocalPostoperative PeriodClinical target volume delineationLower thoracic esophageal carcinomasPostoperative lymph node metastasisReal-world study

Identifiers

PMID35248100
PMCPMC8898421
OpenAlexW4220953375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.